Overview
flowchart TD
companies_biogen["Biogen"]
style companies_biogen fill:#4fc3f7,stroke:#333,color:#000
companies_biogen_0["Company Overview"]
companies_biogen -->|"includes"| companies_biogen_0
style companies_biogen_0 fill:#81c784,stroke:#333,color:#000
companies_biogen_1["Alzheimers Disease Pipeline"]
companies_biogen -->|"includes"| companies_biogen_1
style companies_biogen_1 fill:#ef5350,stroke:#333,color:#000
companies_biogen_2["Approved Therapies"]
companies_biogen -->|"includes"| companies_biogen_2
style companies_biogen_2 fill:#ffd54f,stroke:#333,color:#000
companies_biogen_3["Pipeline Programs"]
companies_biogen -->|"includes"| companies_biogen_3
style companies_biogen_3 fill:#ce93d8,stroke:#333,color:#000
companies_biogen_4["Parkinsons Disease Pipeline"]
companies_biogen -->|"includes"| companies_biogen_4
style companies_biogen_4 fill:#4fc3f7,stroke:#333,color:#000
companies_biogen_5["Cinpanemab BIIB054"]
companies_biogen -->|"includes"| companies_biogen_5
style companies_biogen_5 fill:#81c784,stroke:#333,color:#000
Biogen Inc. is a multinational biotechnology company headquartered in Cambridge, Massachusetts, specializing in neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease. [@biogen]
Company Overview
...Overview
Mermaid diagram (expand to render)
Biogen Inc. is a multinational biotechnology company headquartered in Cambridge, Massachusetts, specializing in neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease. [@biogen]
Company Overview
| Attribute | Details |
|-----------|---------|
| Founded | 1978 |
| Headquarters | Cambridge, Massachusetts, USA |
| Ticker | NASDAQ: BIIB |
| CEO | Christopher Viehbacher |
| Employees | ~7,500 |
| Market Cap | ~0 billion (2024) |
Alzheimer's Disease Pipeline
Approved Therapies
- Leqembi (lecanemab) — Approved in January 2023, developed jointly with Eisai
- Target: [Amyloid-beta](/proteins/amyloid-beta) plaques
- Mechanism: Monoclonal antibody binding to protofibrils
- Phase: Full approval (accelerated → conventional)
- Indication: Early Alzheimer's disease
- [ClinicalTrials.gov: NCT03887455](https://clinicaltrials.gov/ct2/show/NCT03887455)
Pipeline Programs
| Drug | Mechanism | Phase | Indication | Status |
|------|-----------|-------|------------|--------|
| Aduhelm (aducanumab) | Anti-amyloid mAb | Approved (withdrawn) | AD | Withdrawn from market (2024) |
| Remternetug | Anti-amyloid mAb | Phase 3 | AD | Active |
| BIIB080 (tau ASO) | Tau antisense oligonucleotide | Phase 1/2 | AD, PSP | Active |
| BIB094 | Tau mAb | Preclinical | AD | Discovery |
Parkinson's Disease Pipeline
| Drug | Mechanism | Phase | Status |
|------|-----------|-------|--------|
| Vipadenant (BIIB014) | Adenosine A2A receptor antagonist | Phase 2 | Discontinued |
| BIIB122 (DNL151) | [LRRK2](/entities/lrrk2) inhibitor | Phase 1b | Completed; partnered with Denali |
| Cinpanemab (BIIB054) | Anti-alpha-synuclein mAb | Phase 2 | Discontinued |
Cinpanemab (BIIB054)
Cinpanemab (formerly BIIB054) is Biogen's monoclonal antibody targeting [alpha-synuclein](/proteins/alpha-synuclein) aggregates for the treatment of Parkinson's disease.
- Mechanism: Monoclonal antibody targeting alpha-synuclein fibrils
- Target: Pathological alpha-synuclein species (oligomers and fibrils)
- Phase: Phase 2 (SPARK study)
- Status: Discontinued after Phase 2 did not meet primary endpoint
SPARK Study (NCT03318523)
The SPARK study was a randomized, double-blind, placebo-controlled Phase 2 trial evaluating cinpanemab in patients with early Parkinson's disease.
- Primary endpoint: Change from baseline in MDS-UPDRS score at 72 weeks
- Result: Did not meet statistical significance for primary endpoint
- Secondary analyses: Showed some evidence of target engagement (reduced CSF alpha-synuclein)
Scientific Rationale
Cinpanemab was designed to bind specifically to pathological forms of alpha-synuclein, including:
- Soluble oligomers (considered highly toxic)
- Fibrillar species that form Lewy bodies
- Cell-to-cell transmitted aggregates
The antibody was intended to neutralize extracellular alpha-synuclein and enhance microglial clearance, potentially preventing the spread of pathology throughout the brain.
Development History
| Year | Event |
|------|-------|
| 2018 | Phase 1 study initiated |
| 2020 | Phase 2 SPARK study initiated |
| 2022 | SPARK results announced — primary endpoint not met |
| 2023 | Program discontinued |
Despite the discontinuation, data from cinpanemab development contributed to understanding alpha-synuclein pathophysiology and informs future anti-synuclein immunotherapy efforts.
Vipadenant (BIIB014): Biogen developed vipadenant, a selective adenosine A2A receptor antagonist for Parkinson's disease. The drug entered Phase 2 clinical trials but was discontinued as part of Biogen's strategic pipeline prioritization. Vipadenant represented Biogen's historical interest in non-dopaminergic Parkinson's therapeutics targeting the purinergic system, specifically the adenosine A2A receptor in the basal ganglia. The program was similar to other A2A antagonist programs in the field, which aimed to improve motor symptoms by blocking adenosine-mediated inhibition of dopaminergic signaling.
[Multiple System Atrophy](/diseases/multiple-system-atrophy) Relevance
Biogen's neuroscience pipeline has potential relevance to [Multiple System Atrophy](/diseases/multiple-system-atrophy) as an α-synucleinopathy:
- BIIB122 (LRRK2 inhibitor): LRRK2 mutations are implicated in some parkinsonian disorders; may have relevance to MSA-P variant
- Tau programs (BIIB080, BIB094): While primarily targeting tauopathies, understanding of tau-α-syn interactions may inform MSA research
- Alpha-synuclein research: Internal expertise in α-syn biology could support future MSA drug discovery
Recent Funding, IPO & M&A Events
Key Financial Events (2022-2024)
| Year | Event | Details |
|------|-------|---------|
| 2023 | Leqembi Launch | First disease-modifying AD therapy; commercial launch in Q1 2023 |
| 2023 | Aduhelm Withdrawal | Biogen voluntarily withdrew marketing authorization in the US |
| 2024 | Sage Therapeutics Divestiture | Sold rare disease business to Alpine Immune Sciences for .65 billion |
| 2024 | CEO Transition | Christopher Viehbacher appointed CEO, succeeding Michel Vounatsos |
- 2021 Peak: ~00/share (Aduhelm approval hype)
- 2024: ~50-200/share range
- Market cap: ~0 billion (2024)
Revenue Trends
| Year | Revenue | Key Drivers |
|------|---------|-------------|
| 2021 | 0.9B | Aduhelm launch |
| 2022 | 0.2B | Leqembi early sales |
| 2023 | .8B | Leqembi growth, Aduhelm decline |
| 2024 | ~.5B | Post-Aduhelm withdrawal |
Recent Financial Highlights
- 2023 Revenue: .8 billion
- 2024 Revenue: ~.5 billion (Leqembi growth offset by Aduhelm decline)
- R&D Spending: ~.5 billion annually
Key Partnerships
Eisai — Co-development and co-commercialization of Leqembi and Aduhelm; 50/50 profit sharing in US, Eisai leads in Japan, Biogen leads in Europe
Denali Therapeutics — LRRK2 inhibitor program (BIIB122); Biogen has option to acquire
Sage Therapeutics — Former partnership for depression programs; sold in 2024
Samsung Biologics — Manufacturing partnership for LeqembiClinical Trial Results
Leqembi CLARITY-AD Trial
- Results: Slowed cognitive decline by 27% at 18 months
- Primary endpoint: CDR-SB change = -0.45 vs placebo (p=0.00005)
- ARIA-E incidence: 21%
- Publication: [New England Journal of Medicine (2022)](https://www.nejm.org/doi/full/10.1056/NEJMoa2212948)
BIIB080 Tau ASO Phase 1
- Results: Dose-dependent reduction in [tau protein](/proteins/tau) in CSF
- Publication: [Nature Medicine (2023)](https://www.nature.com/articles/s41591-023-02310-9)
Topline Results Database
- [Biogen Clinical Trials](https://www.biogen.com/en_us/clinical-trials.html)
Pipeline Strategy
Biogen's neurodegenerative pipeline focuses on:
Amyloid-targeting — Continuation of anti-amyloid approach with Leqembi and Remternetug
Tau — Developing tau-targeting therapies (BIIB080 ASO and BIB094 mAb)
Neuroprotection — Small molecules for neuroprotection
Regeneration — Focus on synaptic function and neuronal healthCross-References
Related Disease Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Early Alzheimer's Disease](/diseases/early-alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Clinical Trials in Alzheimer's Disease](/clinical-trials/alzheimers-disease)
- [CLARITY-AD Trial](/clinical-trials/clarity-ad)
- [MSA Treatment](/therapeutics/multiple-system-atrophy-msa-treatment)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- [Amyloid-Beta Plaques](/mechanisms/amyloid-beta-plaques)
External Links
- [Biogen Corporate Website](https://www.biogen.com)
- [Leqembi Prescribing Information](https://www.leqembi.com/)
- [Biogen Clinical Trials](https://www.biogen.com/en_us/clinical-trials.html)
References
Unknown, Biogen Corporate Website (n.d.)
Unknown, Leqembi Prescribing Information (n.d.)
Unknown, CLARITY-AD Phase 3 Trial Results (n.d.)
Unknown, Biogen 2023 Annual Report (2023)
Unknown, Biogen Divests Rare Disease Business (2024) (2024)Pathway Diagram
The following diagram shows the key molecular relationships involving Biogen discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)